Cannabinoid Overdose Treatment Using a CB1-Modulating Compound
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The increasing number of emergency room visits due to cannabinoid overdoses, particularly THC and synthetic cannabinoids, necessitates effective treatment methods to alleviate symptoms such as impaired motor coordination, euphoria, and loss of alertness.
Innovation Solution
Administering a therapeutically-effective amount of a compound with specific structures, such as N-(tert-butyl)-3-((4-chlorophenyl)(2-(trifluoromethyl)phenyl)methoxy)azetidine-1-carboxamide, either alone or in combination with THC, to reduce the effects of acute cannabinoid intoxication, measured by improvements in metrics like body sway, heart rate, and visual analog scale assessments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cannabinoid (THC) is administered to achieve therapeutic effects, then pain relief and other therapeutic benefits are improved, but acute cannabinoid intoxication symptoms worsen
Solution Approach 1:
The patent introduces a second compound as an intermediary substance that modulates the effects of the first cannabinoid compound. This mediator compound interacts with the cannabinoid receptor system to attenuate intoxication symptoms while preserving therapeutic benefits, effectively mediating between the therapeutic action and harmful side effects.
Solution Approach 2:
The patent changes the pharmacological parameters by introducing a compound with different binding characteristics and efficacy profile. The second compound has lower efficacy at CB1 receptors compared to the first compound, thereby changing the overall parameter profile of the cannabinoid system to reduce intoxication while maintaining therapeutic effects.
2Reliability
If high dose cannabinoid is administered to treat severe symptoms, then therapeutic effectiveness is improved, but loss of alertness and motor coordination worsen
Solution Approach 1:
The second compound acts as a moderating intermediary that allows higher doses of the first compound to be administered without proportionally increasing motor coordination impairment. The mediator compound buffers the intoxicating effects while permitting therapeutic dosing.
Solution Approach 2:
The patent uses a compound that replicates some of the therapeutic effects of high-dose cannabinoid while copying fewer of the harmful side effects. The second compound creates a partial copy of the therapeutic action without fully replicating the motor coordination impairment.
3Reliability
If cannabinoid treatment is continued to maintain therapeutic effect, then pain relief is improved, but duration of intoxication symptoms increases
Solution Approach 1:
The patent employs periodic or alternating administration of two compounds with different pharmacokinetic profiles. The second compound has a shorter duration of action that allows for periodic modulation of the therapeutic effect, maintaining pain relief while limiting the duration of intoxication symptoms through staggered dosing intervals.
Solution Approach 2:
The patent changes the temporal parameters of cannabinoid action by introducing a compound with different half-life and duration characteristics. This parameter change allows sustained therapeutic effect through the first compound while the second compound's shorter duration limits prolonged intoxication.
Data Source
AI summary
Provided herein are methods of treating cannabinoid intoxication. Further provided herein are metrics for evaluation Cannabis intoxication and the amelioration thereof.